EGFR and squamous cell carcinoma: Jimeno and co-workers (Jimeno et al, 2007) demonstrated that the combination of temsirolimus and erlotinib results in a synergistic antitumour effect against squamous cell carcinoma cell lines, sensitive or resistant to EGFR inhibitors.